SCHEMBL217227

SCHEMBL217227

Cc1ccc(N(C(=O)c2nc[nH]c2C(N)=O)c2nc3ccccc3[nH]2)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 5/20 0.36
PKM P14618 2/20 0.36
USP2 O75604 1/20 0.35
RAB9A P51151 6/20 0.35
NPC1 O15118 5/20 0.35
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
HTT P42858 3/20 0.35
RECQL P46063 2/20 0.35
HPGD P15428 2/20 0.35
MAPT P10636 2/20 0.35
AHR P35869 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
THRB P10828 1/20 0.34
OPRK1 P41145 1/20 0.33
KLF5 Q13887 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216492 0.93 POLB (0.37) POLBSMN1; SMN2PKMUSP2RAB9A
SCHEMBL214715 0.90 POLB (0.40) POLBSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL213394 0.89 POLB (0.48) POLBSMN1; SMN2PKMRAB9ANPC1
SCHEMBL215550 0.88 MAP2 (0.34) SMN1; SMN2MEN1KMT2AKDM4EMAPT
SCHEMBL216070 0.87 POLB (0.47) POLBSMN1; SMN2PKMRAB9ANPC1
SCHEMBL216235 0.87 KDM4E (0.38) POLBRAB9ANPC1ALDH1A1KDM4E
SCHEMBL215785 0.87 POLB (0.41) POLBSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL215596 0.86 POLB (0.38) POLBSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL214939 0.85 POLB (0.36) POLBRAB9ANPC1MEN1KMT2A
SCHEMBL214338 0.85 POLB (0.36) POLBSMN1; SMN2PKMRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 POLB 3464/4885SMN1; SMN2 2516/4885PKM 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.